| |
| |
|
| Insider
Information: |
Paul Steven M |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,185,025 |
|
|
Indirect Shares
|
632,151 |
|
|
| Direct
Value |
$39,384,943 |
|
|
|
Indirect Value
|
$32,026,074 |
|
|
| Total
Shares |
1,817,176 |
|
|
| Total
Value |
$71,411,017 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eli Lilly & Co |
LLY |
EVP, Science and Techn... |
2010-02-01 |
38,897 |
2010-02-01 |
39,040 |
Premium* |
|
|
Sigma-Aldrich Corp |
SIAL |
Director |
2015-11-18 |
0 |
2007-01-02 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2019-03-21 |
272,777 |
2022-11-28 |
593,111 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2022-04-01 |
1,000 |
2015-01-26 |
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
President and CEO, Dir... |
2016-01-14 |
872,351 |
|
0 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
131 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2006-04-25 |
4 |
S |
$52.06 |
$1,301,507 |
D/D |
(25,000) |
39,656 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2009-12-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
28,854 |
5,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2009-12-23 |
5 |
GA |
$0.00 |
$0 |
I/I |
28,854 |
37,407 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-02-10 |
4 |
AS |
$130.00 |
$3,900,000 |
D/D |
(30,000) |
1,000 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-02-10 |
4 |
OE |
$14.67 |
$440,100 |
D/D |
30,000 |
31,000 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-03-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
30,304 |
2,364 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-03-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,304 |
30,304 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-02-23 |
4 |
OE |
$7.27 |
$599,675 |
D/D |
31,518 |
42,114 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-01-17 |
4 |
A |
$52.86 |
$1,693,634 |
D/D |
32,040 |
71,696 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2008-01-25 |
4 |
A |
$50.74 |
$2,245,549 |
D/D |
44,256 |
81,296 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-02-29 |
4 |
A |
$315.18 |
$14,932,598 |
I/I |
47,378 |
70,608 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-10-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
48,257 |
2,049 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-10-14 |
4 |
GA |
$0.00 |
$0 |
D/D |
48,257 |
76,919 |
|
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2019-02-15 |
4 |
AS |
$161.02 |
$7,964,210 |
I/I |
(49,461) |
74,443 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,249 |
56,249 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2019-03-20 |
4 |
AS |
$161.20 |
$9,136,582 |
I/I |
(56,646) |
130,279 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2018-03-06 |
4 |
AS |
$172.00 |
$9,999,908 |
D/D |
(58,139) |
632,712 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-03-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
60,608 |
32,668 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-03-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
60,608 |
10,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-05-21 |
4 |
D |
$59.60 |
$5,568,726 |
D/D |
(93,435) |
44,705 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
President & CEO |
• • – |
2019-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
96,485 |
106,485 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-05-21 |
4 |
OE |
$54.80 |
$5,370,838 |
D/D |
98,008 |
138,140 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
CSO and President of R&D |
• • – |
2022-05-27 |
4 |
GA |
$0.00 |
$0 |
I/I |
106,485 |
106,485 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
CSO and President of R&D |
• • – |
2022-05-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
106,485 |
0 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
CSO and President of R&D |
• • – |
2022-05-31 |
4 |
GD |
$0.00 |
$0 |
I/I |
106,485 |
0 |
0 |
- |
|
131 Records found
|
|
Page 5 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
